A tetraspecific VHH-based neutralizing antibody modifies disease outcome in three animal models of clostridium difficile infection

Diane J. Schmidt, Gillian Beamer, Jacqueline M. Tremblay, Jennifer A. Steele, Hyeun Bum Kim, Yaunkai Wang, Michele Debatis, Xingmin Sun, Elena A. Kashentseva, Igor P. Dmitriev, David T. Curiel, Charles B. Shoemaker, Saul Tzipori

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Clostridium difficile infection (CDI), a leading cause of nosocomial infection, is a serious disease in North America, Europe, and Asia. CDI varies greatly from asymptomatic carriage to life-threatening diarrhea, toxic megacolon, and toxemia. The incidence of community-acquired infection has increased due to the emergence of hypervirulent antibiotic-resistant strains. These new strains contribute to the frequent occurrence of disease relapse, complicating treatment, increasing hospital stays, and increasing morbidity and mortality among patients. Therefore, it is critical to develop new therapeutic approaches that bypass the development of antimicrobial resistance and avoid disruption of gut microflora. Here, we describe the construction of a single heteromultimeric VHH-based neutralizing agent (VNA) that targets the two primary virulence factors of Clostridium difficile, toxins A (TcdA) and B (TcdB). Designated VNA2-Tcd, this agent has subnanomolar toxin neutralization potencies for both C. difficile toxins in cell assays. When given systemically by parenteral administration, VNA2-Tcd protected against CDI in gnotobiotic piglets and mice and to a lesser extent in hamsters. Protection from CDI was also observed in gnotobiotic piglets treated by gene therapy with an adenovirus that promoted the expression of VNA2-Tcd.

Original languageEnglish
Pages (from-to)774-784
Number of pages11
JournalClinical and Vaccine Immunology
Volume23
Issue number9
DOIs
StatePublished - Sep 2016

Fingerprint

Dive into the research topics of 'A tetraspecific VHH-based neutralizing antibody modifies disease outcome in three animal models of clostridium difficile infection'. Together they form a unique fingerprint.

Cite this